

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
31 July 2025 (31.07.2025)



(10) International Publication Number
WO 2025/158412 A1

- (51) **International Patent Classification:**
A61K 47/54 (2017.01) *A61P 37/06* (2006.01)
- (21) **International Application Number:**
PCT/IB2025/050867
- (22) **International Filing Date:**
26 January 2025 (26.01.2025)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
- | | | |
|------------|------------------------------|----|
| 63/625,882 | 26 January 2024 (26.01.2024) | US |
| 63/652,605 | 28 May 2024 (28.05.2024) | US |
| 63/677,726 | 31 July 2024 (31.07.2024) | US |

(71) **Applicant: BIOHAVEN THERAPEUTICS LTD.**
[US/GB]; P.O. Box 173, Kingston Chambers, Road Town,
Tortola, VG1110 (VG).

(72) **Inventors: LINHARES, Brian M.;** Biohaven Pharmaceu-
ticals, Inc., 215 Church Street, New Haven, Connecticut
06510 (US). **SILVERMAN, Julie;** Biohaven Pharmaceu-
ticals, Inc., 215 Church Street, New Haven, Connecticut
06510 (US). **INGALE, Sampat;** Biohaven Pharmaceu-
ticals, Inc., 215 Church Street, New Haven, Connecticut
06510 (US). **KAZMIERSKI, Wieslaw;** Biohaven Phar-
maceuticals, Inc., 215 Church Street, New Haven, Con-
necticut 06510 (US). **BRYSON, James;** Biohaven Pharma-
ceuticals, Inc., 215 Church Street, New Haven, Connecti-
cut 06510 (US). **KARAGIANNI, Korina;** Biohaven Phar-
maceuticals, Inc., 215 Church Street, New Haven, Con-
necticut 06510 (US). **YOUSEF, Hanna;** Biohaven Pharma-
ceuticals, Inc., 215 Church Street, New Haven, Connecti-
cut 06510 (US). **HEAD, Jared;** Biohaven Pharmaceuticals,
Inc., 215 Church Street, New Haven, Connecticut 06510
(US). **MARCIN, Lawrence R.;** Biohaven Pharmaceuticals,
Inc., 215 Church Street, New Haven, Connecticut 06510
(US).

(74) **Agent: ZUEV, Dmitry;** Biohaven Pharmaceuticals, Inc.,
215 Church Street, New Haven, Connecticut 06510 (US).

(81) **Designated States** (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,

MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN,
WS, ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))*
- *in black and white; the international application as filed
contained color or greyscale and is available for download
from PATENTSCOPE*

(54) **Title:** BIFUNCTIONAL DEGRADERS OF IgG4 IMMUNOGLOBULINS

(57) **Abstract:** A composition of matter including an IgG4-binding moiety, a cellular receptor-binding moiety which binds to hepato-
cytes or other degrading cells through asialoglycoprotein receptors (ASGPR) on the surface of hepatocytes or other degrading cells
in a patient or subject, and optionally, a linker moiety connecting the IgG4-binding moiety and the cellular receptor-binding moiety,
wherein the composition of matter is useful for removing IgG4 from a subject or patient.

WO 2025/158412 A1